Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

Region:North America

Author(s):

Product Code:GDPH1307FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

March 2019

Total pages

71

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

Biogen Inc (BIIB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases. The company's marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Alzheimer's disease and idiopathic pulmonary fibrosis, and stroke among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc Key Recent Developments

Mar 12,2019 Biogen to sell biologics production site to Fujifilm for USD 890m

Mar 04,2019 Biogen to buy gene therapy firm Nightstar Therapeutics for USD 800m

Mar 01,2019 Biogen Responds to CADTH's updated recommendation regarding coverage for SPINRAZA

Feb 28,2019 Biogen Further Expands Presence in China with Approval of SPINRAZA (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

Biogen Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Merck & Co Inc

United Neuroscience Ltd

Teva Pharmaceutical Industries Ltd

Bayer HealthCare Pharmaceuticals

Pfizer Inc

Sanofi

Dart NeuroScience LLC

Alzheon Inc

Table of Contents

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Biogen Inc-Key Facts

Biogen Inc-Key Employees

Biogen Inc-Key Employee Biographies

Biogen Inc-Major Products and Services

Biogen Inc-History

Biogen Inc-Company Statement

Biogen Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Biogen Inc-Business Description

Product Category: Biosimilars

Overview

Performance

Product Category: Multiple Sclerosis

Overview

Performance

Product Category: Others

Overview

Performance

Product Category: Spinal Muscular Atrophy

Overview

Performance

Geographical Segment: Asia

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Other

Performance

Geographical Segment: US

Performance

R&D Overview

Biogen Inc-Corporate Strategy

Biogen Inc-SWOT Analysis

SWOT Analysis-Overview

Biogen Inc-Strengths

Biogen Inc-Weaknesses

Biogen Inc-Opportunities

Biogen Inc-Threats

Biogen Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Biogen Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Mar 12, 2019: Biogen to sell biologics production site to Fujifilm for USD 890m

Mar 04, 2019: Biogen to buy gene therapy firm Nightstar Therapeutics for USD 800m

Mar 01, 2019: Biogen Responds to CADTH's updated recommendation regarding coverage for SPINRAZA

Feb 28, 2019: Biogen Further Expands Presence in China with Approval of SPINRAZA (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

Jan 29, 2019: Biogen reports record revenues for both the full year and Q4 2018, USD 13.5 billion and USD 3.5 billion, respectively

Jan 07, 2019: Biogen signs two deals to address neurological disorders

Dec 06, 2018: Top Canadian researchers at the helm of pioneering Canadian Proactive Cohort Study for People Living with MS (CanProCo)

Nov 29, 2018: International Prix Galien Recognizes SPINRAZA as Best Biotechnology Product

Nov 29, 2018: International Prix Galien Recognizes SPINRAZA as Best Biotechnology Product

Nov 19, 2018: Biogen and Amicus win UK Prix Galien awards for rare disease medicines

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List of Figure

List of Figures

Biogen Inc, Performance Chart (2014-2018)

Biogen Inc, Ratio Charts

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List of Table

List of Tables

Biogen Inc, Key Facts

Biogen Inc, Key Employees

Biogen Inc, Key Employee Biographies

Biogen Inc, Major Products and Services

Biogen Inc, History

Biogen Inc, Other Locations

Biogen Inc, Subsidiaries

Biogen Inc, Joint Venture

Biogen Inc, Key Competitors

Biogen Inc, Ratios based on current share price

Biogen Inc, Annual Ratios

Biogen Inc, Annual Ratios (Cont...1)

Biogen Inc, Annual Ratios (Cont...2)

Biogen Inc, Interim Ratios

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Biogen Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022